All In Biotech

Drug Trial Radar · NCT05919680

A Study of NST-6179 in Subjects With Intestinal Failure-Associated Liver Disease (IFALD).

A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Orziloben (NST-6179) in Subjects With Intestinal Failure-Associated Liver Disease (IFALD)

Last checked: Nov 20, 2026Latest source record: Jan 7, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

36

Planned (sponsor's estimate)

Start

Jan 15, 2024

Primary completion

Jun 30, 2025

Study completion Jun 30, 2025

Sponsor

Lead sponsor
NorthSea Therapeutics B.V.Industry
Sponsor type
Industry
First posted
Jun 26, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 16 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 2a, multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of NST-6179 in subjects with intestinal failure-associated liver disease (IFALD) receiving parenteral nutrition (PN). The study will be conducted in 2 sequential parts. Up to 36 subjects diagnosed with IFALD will be enrolled in the study, of which up to 18 subjects will be enrolled in each of the 2 parts and randomized (2:1) to receive NST-6179 (N=12/part) or matched placebo (N=6/part). Subjects in Part A will receive once daily (QD) oral administration of 800 mg (32 mL solution) NST-6179 or placebo for 4 weeks. The NST-6179 dose for Part B is planned to be 1200 mg QD for 12 weeks. Actual dose, however, will be determined during the safety review meeting.

Conditions

  • Intestinal Failure Associated Liver Disease

Interventions

  • NST-6179 Part ADrug

    Once daily (QD) oral administration of 800mg (32 mL solution) of NST-6179 for 4 weeks

  • NST-6179 Part BDrug

    Once daily (QD) oral administration of 1200mg of NST-6179 for 12 weeks

  • Matched PlaceboOther

    Matched placebo for administration in Part A or Part B

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To assess the safety and tolerability of NST-6179Time frame: Up to 14 Weeks
  2. To assess the pharmacokinetics of NST-6179Time frame: Day 1 and Day 14
  3. To assess the pharmacodynamic effects of NST-6179 on hepatic steatosisTime frame: 12 weeks
  4. To assess the pharmacodynamic effects of NST-6179 on hepatic inflammationTime frame: 12 weeks
  5. To assess the pharmacodynamic effects of NST-6179 on hepatic cholestasis (bilirubin, ALP, GGT)Time frame: 12 weeks
  6. To assess the pharmacodynamic effects of NST-6179 on hepatic fibrosis (ELF, Pro-C3, FIB-4)Time frame: 12 weeks

Locations

13 sites in 1 country. Site status is shown where the registry gives one.

  • Mayo Clinic Scottsdale Campus

    Scottsdale, Arizona · Recruiting

  • University of California San Francisco Medical Center

    San Francisco, California · Recruiting

  • MedStar Georgetown University Hospital

    Washington D.C., District of Columbia · Not yet recruiting

  • Emory University School of Medicine

    Atlanta, Georgia · Recruiting

  • The University of Chicago Medical Center

    Chicago, Illinois · Recruiting

  • Boston Children's Hospital

    Boston, Massachusetts · Recruiting

  • Henry Ford Hospital

    Detroit, Michigan · Recruiting

  • Mayo Clinic Rochester Campus

    Rochester, Minnesota · Recruiting

  • Mount Sinai Medical Center

    New York, New York · Recruiting

  • Duke University Medical Center

    Durham, North Carolina · Recruiting

  • The Cleveland Clinic

    Cleveland, Ohio · Recruiting

  • Vanderbilt University School of Medicine

    Nashville, Tennessee · Recruiting

  • University of Washington

    Seattle, Washington · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.